Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter to purchase Prism Pharmaceuticals

Baxter to purchase Prism Pharmaceuticals

20th April 2011

Baxter has announced plans to acquire Prism Pharmaceuticals, a US-based drug manufacturer, for a total consideration of up to $338 million (206.76 million pounds).

The deal is expected to close in the second quarter of 2011 and will allow Baxter to gain control of Nexterone, an innovative antiarrhythmic agent for the treatment of several cardiovascular conditions.

This product has already received approval from US healthcare regulators in a number of presentations, including the first and only ready-to-use premixed intravenous bag formulations of the treatment available in the territory.

Robert Davis, president of Baxter's medical products business, said the company's familiarity with Nexterone makes it ideally placed to continue expanding the range.

"Nexterone is a great addition to our leading portfolio of premix drugs and solutions for the acute care setting," he added.

Earlier this month, Baxter reported positive clinical trial data from a new study of the fibrin sealant product Artiss, which can help to improve tissue adherence during facial surgery.ADNFCR-8000103-ID-800506926-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.